France Optic Nerve Disorders Treatment Market Size & Outlook, 2026-2034
France Optic Nerve Disorders Treatment Market Insights
- According to Reed Intelligence analysis, the France Optic Nerve Disorders Treatment Market size was USD 153.66 Million in 2025 and is projected to reach USD 277.85 Million by 2034.
- The France market is projected to grow at a CAGR of 6.87% between 2026 and 2034.
- By segment, Glaucoma-Associated Optic Neuropathy emerged as the largest Disease Type in terms of market size in 2025.
- Other Optic Nerve Disorders is anticipated to remain the most attractive Disease Type segment, recording the fastest growth during the forecast period.
![France Optic Nerve Disorders Treatment Market Size, Share & Growth Analysis By [2034]](https://reedintelligence.com/uploads/charts/france-optic-nerve-disorders-treatment-market-france-disease-type-111069.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, France held 4.49% of the global Optic Nerve Disorders Treatment Market size.
- By 2034, United States is anticipated to capture the largest share of the global Optic Nerve Disorders Treatment Market.
- In Europe, Germany is expected to lead the regional Optic Nerve Disorders Treatment Market size by 2034.
- Spain will remain the fastest-growing market in Europe, reaching USD 151.05 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 153.66 Million |
| Market Size In 2034 | USD 277.85 Million |
| Largest segment | Glaucoma-Associated Optic Neuropathy |
| Units | Revenue in USD Million |
| CAGR | 6.87% (2026-2034) |
| Segmnetation Covered | |
| Disease Type |
|
| Treatment Type |
|
| End User |
|
| Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Optic Nerve Disorders Treatment Market Disease Type 2026-2034 (USD Million)
| Disease Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaucoma-Associated Optic Neuropathy | XX.x | XX.x | XX.x | 56.64 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Optic Neuritis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ischemic Optic Neuropathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Traumatic Optic Neuropathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Optic Nerve Disorders | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Optic Nerve Disorders Treatment Market Treatment Type 2026-2034 (USD Million)
| Treatment Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical Therapies | XX.x | XX.x | XX.x | 71.49 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Surgical Treatments | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biologic Regenerative Therapies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Optic Nerve Disorders Treatment Market End User 2026-2034 (USD Million)
| End User | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 69.46 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Ophthalmology Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Optic Nerve Disorders Treatment Market Distribution Channel 2026-2034 (USD Million)
| Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital Pharmacies | XX.x | XX.x | XX.x | 70.46 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Retail Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Pharmacies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
